Nyxoah S.A. (NYXH)
Nyxoah S.A. operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Mont-Saint-Guibert, WA, BE. The stock last traded at $1.58, down 0.63% on the session, giving a market capitalisation of $158.1M. On trailing twelve-month figures it carries a trailing P/E of -0.63, a net margin of -434.7%. Its beta of 0.95 implies it has historically moved less than the broad market.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A. is most often compared with the following Healthcare names: